Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
CHA University
CHA University
CHA University
CHA University
AstraZeneca
National Institutes of Health Clinical Center (CC)
Peking University
Aarhus University Hospital
Eisai Inc.
Ankara Etlik City Hospital
National Health Research Institutes, Taiwan
AstraZeneca
AstraZeneca
Tata Memorial Centre
Mayo Clinic
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Shanghai Zhongshan Hospital